Ingenuity Systems, a 15-year veteran of the biological software business, showed today that you can make money not just by generating DNA data, but by helping scientists figure out what it means.
Redwood City, CA-based Ingenuity said today it has agreed to be acquired by Netherlands-based Qiagen for $105 million in cash. Ingenuity, a private company, was able to fetch that price after it closed last year with about $20 million in net sales, the companies said in a statement. The deal is expected to start adding to Qiagen’s profits in 2015, the companies said.
Location: Morgan, Lewis & Bockius Conference Center, 1111 Pennsylvania Ave., NW Washington, DC 20004-2541
National Brain Tumor Society is bringing together brain tumor researchers and industry executives to discuss how to move research from bench to bedside.
Biophrama executives and VC investors will share their criteria for investment and licensing of academic research.
Panelists include:
Lauren Abrey Global Development Team Lead, Genetech/Roche
Neil Exter Partner, Third Rock
Brian Gallagher Partner, SROne
Michael Glutch Managing Director, Medimmune Ventures
Perry Nisen Senior VP of Science Transactions, Pfizer
Nation Brain Tumor Society-funded researchers will present brain tumor drug candidates ready for early stage investment and/or licensing.
The Maryland Technology Enterprise Institute (Mtech) today announces the winners of the inaugural University of Maryland Business Model Challenge.
The two winning UMD entrepreneur teams were selected from among 44 initial entries and 11 finalist teams, six of whom were selected to present the results they achieved through the Challenge’s multi-week lean startup workshop to an expert panel of judges on April 26 at the University of Maryland.
Late last week, leaders from across the global vaccine industry gathered at the 6th Annual Vaccine Industry Excellence (ViE) awards ceremony during the World Vaccine Congress in Washington, D.C, to honor the industry’s best and brightest. Immunovaccine is proud to announce that chief executive officer John Trizzino was awarded this year’s Best Biotech CEO prize during the ceremony.
In considering candidates for the Best Biotech CEO award, judges evaluated a number of important criteria including:
Degree of outstanding commitment to disease prevention and treatment
Level of exemplary leadership throughout the year
Contribution to company performance, communication and vision
Influence within the industry
Achievements made with regards to company positioning and status
The Ernst & Young Entrepreneur Of The Year 2013 finalists have a lot to celebrate. They’ve built their dream companies. Expanded. Innovated. And now Ernst & Young is recognizing them for their achievements. Help us congratulate these outstanding entrepreneurs. Join us at this years event and see who will take home top honors.
Johns Hopkins says it is working on its largest-ever fundraising campaign, which aims to raise $4.5 billion by the end of 2017.
The university and health system announced the effort Saturday. The idea is to create as many as 300 endowed professorships and generate nearly $700 million for undergraduate financial aid and graduate student fellowships.
Leveraging USDA-ARS Partnerships and Capabilities to Help Your Business
PRESENTERS:
Robert Griesbach, Ph.D. Deputy Assistant Administrator Office of Technology
James Poulos, III Technology Transfer Coordinator
Cathy Cohn Technology Transfer Liaison
Abstract:
Agricultural Research Services (ARS) is the research arm of the Department of Agriculture that develops and transfers solutions to agricultural problems affecting Americans every day, from field to table. To accelerate the development of new products and help move technologies into the marketplace, ARS often partners with companies and research institutions early on in the research process. Working collaboratively alongside ARS, partners are able access and implement ARS technologies, resources and expertise to further develop specific products and create new ones. ARS conducts research in 800 projects at 90 locations including six pilot plants and six human nutrition centers. With a long standing commitment to technology transfer, ARS works closely with the private sector to ensure research outcomes are adopted. Please join us to learn about the wide range of expertise and capabilities from ARS that can be used to grow your business
Emergent BioSolutions Inc. (NYSE:EBS) announced its participation in the Defence against Terrorism Programme of Work (DAT POW) workshop conducted by the North Atlantic Treaty Organization (NATO) Emerging Security Challenges Division at the Counter Terror Expo in London. An initial session of the workshop was focused on the future capabilities and protection of the Special Operations Forces (SOF) community on areas such as Improvised Explosive Devices (IEDs), Intelligence, Surveillance, Reconnaissance (ISR), Biometrics and Forensics, Information Sharing Systems, Tactical Computer, Communications, Command and Control (C4), and Force Protection.
“Emergent strongly supports NATO’s initiatives to educate on protecting those who protect the population,” said Allen Shofe, Executive Vice President of Corporate Affairs, Emergent BioSolutions. “NATO DAT POW workshops are highly relevant and informative as they cover various activities undertaken and coordinated by NATO countries.”
The University of Maryland Institute for Bioscience and Biotechnology Research (IBBR) invites you to participate in the 5th Biennial NMR Day symposium on Friday, May 17, 2013, at our facility in Rockville, Maryland.
IBBR (formerly CARB) hosts a biennial meeting, designed to promote discussion and collaboration among scientists active in the application of biomolecular NMR to modern problems in structural biology and biotechnology. The symposium speakers are internationally recognized in the application of NMR to biological systems
The National Capitol Area Local Chapter of SoPE in concert with JHU Carey Business School, MedChi, Zanvyl Krieger School of Arts and Sciences Center for Biotechnology Education, Montgomery County Medical Society, and the Medical Society of Northern Virginia presents:
“Working with Industry in the Life Sciences – What does it Really Take?”
Tuesday, May 14th, 2013–6:00PM to 8:00PM
Johns Hopkins University, Montgomery County Campus, Building III – 9605 Medical Center Drive, Room 121
Join us as we bring together top leaders and innovators in the fields of Cybersecurity, Health IT, and Mobile Technology. Learn where the technology is leading these 3 sectors and the opportunities that exist for real estate brokers and developers who want to capitalize on these expanding industries.
Hear from leaders including Dr. Freeman Hrabowski, one of Time Magazine’s “World’s 100 Most Influential People”, as well as Dr. Mark Doms, Under Secretary for Economic Affairs with the United States Department of Commerce, who serves as a top economic advisor to the Obama Administration and to the Department of Commerce.
Startup Maryland today announced dates (September 9 – 27) and the rough route for the Pitch Across Maryland 2.0, the second annual state-wide tour and celebration of entrepreneurship and startup companies.
Referred to by CBS News affiliate WBOC-TV 16 as “Opportunity on Wheels,” the inaugural Pitch Across Maryland tour was an overwhelming success last year. The bus traversed the state all in the name of celebrating entrepreneurship. A sampling of details, key data and results from last year’s tour follow:
The Johns Hopkins Bloomberg School of Public Health has partnered with Barclays Bank to develop a youth entrepreneurship program with the Bloomberg School’s Center for American Indian Health. The new initiative is aimed at designing an evidence-based program to inspire American Indian youth to stay in school and create business and social entrepreneurship opportunities.
As part of the partnership, Barclays will provide a total of $1.2 million in program funding over the course of the next three years. Additionally, Barclays employees will lend their business expertise and serve as mentors to program participants. Program efforts will first concentrate on the White Mountain Apache Reservation in Arizona with the ultimate goal to implement youth entrepreneurship programs in poverty stricken communities throughout the world.
Earlier this month, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for the first quarter of 2013. The report, which is prepared by NVCA and PriceWaterhouseCoopers LLP using data from Thomson Reuters, indicates that venture capitalists invested $5.9 billion in 863 deals in the first quarter, which constituted a 12% decrease in dollars and a 15% decrease in deals as compared with the fourth quarter of 2012, when $6.7 billion was invested in 1,013 deals (see chart below; data from MoneyTree Reports).
Somewhere between venture funding and bank loans is a kind of investment that seems to fly under the radar, but apparently over the last several years has become increasingly popular for biotech companies beyond the startup stage looking for growth capital.
Royalty financing is the vehicle that Capital Royalty L.P. will use to invest its new $805 million fund in healthcare products and technologies. But (sorry startups), it’s not looking for early-stage companies. Capital Royalty says it invests in companies with FDA-approved healthcare products that are generating revenue. These are companies looking to make acquisitions, expand into new markets or develop new products with investments of $20 million to $200 million.
Chandra Duggirala, maker of an experimental device for type two diabetes, is on the verge of giving up.
Duggirala’s company, Novobionics, raised a small amount of funding for a noninvasive technology that mimics the effects of gastric bypass surgery. The device tricks the gastro-intestinal tract into thinking it is full, which slows the rate of nutrient absorption, thereby easing suffering for diabetes patients.
President Barack Obama dropped in on the National Academy of Sciences today to help it celebrate its 150th birthday.
The president said he’s committed to increased public investment in scientific research, contending this is necessary in order for the U.S. to retain its technological edge. Under sequestration, however, federal spending on research is being cut, not increased.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
